Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, pre-vent and/or ameliorate HIV infection and/or AIDS.

Abstract: There is described an artificial heart comprising a pump, the pump comprising a housing (10) defining a substantially spherical cavity and comprising four vascular connectors (15in, 15out, 15?in, 15?out), namely two inlet connectors (15in, 15?in) and two outlet connectors (15out, 15?out) to connect the pump to the pulmonary and systemic circulation. A rotatable disc (11) is mounted within the housing (10) and secured to rotate about a fixed axis (12). Two oscillating palettes (16a, 16b) are mounted to rotate about a mobile axis (17) movable within a plane perpendicular to the fixed axis (12), wherein said palettes (16a, 16b) are connected together and are arranged on both sides of the rotatable disc (11), in a diametrically opposed fashion, to create two pumping units comprising each two variable sized chambers (20a, 20b, 20c, 20d) in fluid communication with one corresponding inlet and outlet connector respectively.

Abstract: The present relates to a computer-implemented method for detecting and predicting cognitive pathologies of the brain based on a “Hold” and “Release” process. The invention also concerns a device related to the claims method.

Abstract: The invention relates to methods promoting the aggregation of Salmonella bacteria in the gut of subjects, thereby providing immune exclusion and limiting bacterial entry, therefore reducing mucosal and systemic infection.

Abstract: In order to reduce the time and effort required to generate high-quality image reconstructions, a machine-trained neural network may assign a quality score to an image at each iteration of a reconstruction. The neural network may confirm that the iterative reconstruction process increases image quality as each iteration converges to the solution of an optimization problem. The image quality score generated by the neural network may drive the reconstruction toward better image quality by contributing to a regularization term of a cost function minimized by the optimization problem. The neural network may allow for multiple reconstruction of image data to be performed rapidly and for the highest image quality reconstruction to be identified. Additionally, the neural network may provide exit criteria of the iterative reconstruction or may contribute to the optimization problem.

Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.

Abstract: A system and method automatically predicts an evolution of a cognitive score for a subject by classifying a cognitive data set for the subject into a first or second class by determining the cognitive set of data for each subject of a group, acquiring for each subject a neuropsychological score used for classifying each subject in the first or second class, and training a two-class machine learning classification algorithm on the cognitive data sets of all subjects. For each subject, the cognitive data set is used as input of the algorithm and the obtained classification of the subject as output target of the algorithm. The algorithm classifies each cognitive data set in the first or second class. The evolution of the cognitive score of a subject is predicted by the trained algorithm for automatically classifying a new cognitive dataset for the subject into the first or second class.

Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.

Abstract: Provided herein are compounds (e.g., compounds of Formulae (I), (II), and (III)) which are anti-fungal agents and can be used in the treatment of diseases, including infectious diseases. The invention provides methods of treating diseases in a subject (e.g., infectious diseases such as fungal infections), and methods of killing or inhibiting the growth of fungi in or on a subject or biological sample. The compounds may be used in subjects, in clinical settings, or in agricultural settings.

Abstract: Selectively exciting bulk protons in certain tissue components, e.g. water, while suppressing the excitation of others, e.g. fat, can lead to images with better contrast for desired features. The invention provides binomial, off-resonance RF excitation pulses for differentiating tissue excitation that yields a larger fat suppression that prior art water excitation methods. Proper balancing of the frequency offset and the pulse duration with a relative phase offset between the pulses leads to large-bandwidth pass- and stopbands for water and fat, respectively. The pulses can be applied with short, or even zero, interpulse delay, leading to substantial time savings in the imaging sequence.

Abstract: The invention relates to chemoembolization compositions for anti-angiogenic agent delivery. The invention further relates to a method of preparing chemoembolization compositions and to the use of chemoembolization compositions in the method for treating solid tumour cancers.

Abstract: The invention relates to methods promoting the aggregation of Salmonella bacteria in the gut of subjects, thereby providing immune exclusion and limiting bacterial entry, therefore reducing mucosal and systemic infection.

Abstract: This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, prevent and/or ameliorate HIV infection and/or AIDS.

Abstract: The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided.

Abstract: The present invention relates to a method for predicting awakening in a comatose patient based on the progression of auditory discrimination during early stages of coma. EEG measures are acquired from the patient during two distinct periods when said patient is exposed to auditory stimuli comprising repeated standard and deviant sounds. The first period occurs when the comatose patient is in a hypothermia state and the second period occurs when the comatose patient is in a normal temperature state and preferably within 2-3 days from the onset of the coma. The present invention further relates to a computer-implemented method thereof.

Abstract: A method improves a detection of a brain tissue pathology in magnetic resonance (MR) images of a patient. The method includes acquiring multiple MR imaging data for creating four different contrast maps of a patient brain. From the multiple MR imaging data, performing an estimation of gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF) concentration for each voxel of a part of the patient brain. From the multiple MR imaging data, segmenting the part of the patient brain in different regions-of-interest (ROIs) according to a chosen atlas. For each voxel of each of the contrast maps of the patient brain, computing, for the part of the patient brain, a deviation score. The method further includes creating from the deviation score and for each of the quantitative contrast maps, a deviation map representing the part of the brain in dependence on the deviation score calculated for each voxel.

Abstract: The invention is in the field of analysis of cell populations and cell separation and the compositions obtained thereby. More particularly, the invention concerns a method for separating cells of interest according to a specific marker expressed on their surface.

Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.

Abstract: The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain and/or a non-viable attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain for use the treatment of cancer recurrence/progression. Preferably the cancer is bladder cancer.

Abstract: A treatment of Huntington's disease (HD) using the Clustered-Regularly Interspaced Short Palindromic Repeats (CRISPR) system. This technology offers the possibility to design a small RNA (sgRNA), which is incorporated into a CRISPR-associated protein (Cas9) to recognize and induce DNA double-strand breaks at a specific target location. In the context of HD, this allows to block the expression of the mutant huntingtin or repair the CAG expansion causing the disease.